N-(1H-indol-5-yl)-2-thiophenecarboxamide profile

ID Source	ID
PubMed CID	2814135
CHEMBL ID	1173146
CHEBI ID	93108

Synonym
MLS-0311872.0001
IDI1_013961
OPREA1_183022
MLS000860606
n-(1h-indol-5-yl)-2-thiophenecarboxamide
smr000458690
MAYBRIDGE3_002574
HMS1438E22
CHEMBL1173146
MLS002460409 ,
n-(1h-indol-5-yl)thiophene-2-carboxamide
AKOS013405044
HMS2203L09
bdbm95997
cid_2814135
HMS3358D10
CHEBI:93108
708987-59-1
2-thiophenecarboxamide,n-1h-indol-5-yl-
Q27164830

Class	Description
indoles	Any compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	9.5283	0.0072	15.7588	89.3584	AID588342
BRCA1	Homo sapiens (human)	Potency	3.1623	0.8913	7.7225	25.1189	AID624202
ATAD5 protein, partial	Homo sapiens (human)	Potency	8.1961	0.0041	10.8903	31.5287	AID504466; AID504467
Microtubule-associated protein tau	Homo sapiens (human)	Potency	10.0000	0.1800	13.5574	39.8107	AID1460
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	8.9125	0.2818	9.7212	35.4813	AID2326
P53	Homo sapiens (human)	Potency	3.5481	0.0731	9.6858	31.6228	AID504706
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	1.5849	0.0126	2.4518	25.0177	AID485313
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	6.5131	0.0041	9.9848	25.9290	AID504444
ras-related protein Rab-9A	Homo sapiens (human)	Potency	1.9953	0.0002	2.6215	31.4954	AID485297
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	7.0795	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	7.0795	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	7.0795	0.1585	5.2879	12.5893	AID540303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
DnaK protein homolog	Escherichia coli	IC50 (µMol)	20,000.0000	2,000.0000	2,000.0000	2,000.0000	AID1494
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
DnaK protein homolog	Escherichia coli	Kd (FL)	12.7000	0.2000	4.8667	12.7000	AID1495
DnaK protein homolog	Escherichia coli	MIC_EC_37	400.0000	400.0000	400.0000	400.0000	AID1503
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID492543	Antibacterial activity against Escherichia coli	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Heat shock protein 70 (hsp70) as an emerging drug target.
AID492542	Binding affinity to Escherichia coli DNAK substrate binding domain by isothermal titration assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Heat shock protein 70 (hsp70) as an emerging drug target.
AID492544	Antibacterial activity against Yersinia pseudotuberculosis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Heat shock protein 70 (hsp70) as an emerging drug target.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes
N-[(2-fluorophenyl)methyl]-2-thiophenecarboxamide [no description available]	3.15	1	aromatic amide; thiophenes
mkt 077 MKT 077: structure given in first source	3.15	1
pyrrhocoricin protein, pyrrhocoris apterus pyrrhocoricin protein, Pyrrhocoris apterus: a 20-residue proline-rich peptide carrying an O-glycosylated substitution; from the sap-sucking bug Pyrrhocoris apterus; active against Gram-negative bacteria; amino acid sequence given in first source	3.15	1

Condition	Relationship Strength	Studies
Degenerative Diseases, Central Nervous System [description not available]	2.97	1
Infection [description not available]	2.97	1
Benign Neoplasms [description not available]	2.97	1
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	2.97	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.97	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.97	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1

N-(1H-indol-5-yl)-2-thiophenecarboxamide

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (16)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.41

Study Types

N-(1H-indol-5-yl)-2-thiophenecarboxamide

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (16)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.41

Study Types

Related Drugs (3)

Related Conditions (8)